From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion-positive Pancreatic Cancer.
Jessica Lucchetti, Paola Cimini, Lorenzo Angotti et al.
✦ AI-curated · Sources linked
Case in brief
A 48-year-old woman with pancreatic ductal adenocarcinoma and liver metastases experienced a significant response to selpercatinib after genomic profiling revealed an NCOA4-RET fusion. Following treatment, she achieved over 50% reduction in tumor size, with sustained regression for more than 12 months despite dose adjustments due to side effects. She remains clinically well with an ECOG performance status of 0.
Diagnostic / clinical pearl
Comprehensive genomic profiling can identify actionable RET fusions in pancreatic cancer, potentially leading to significant therapeutic responses.
Why it matters
This case highlights the importance of genomic insights in personalizing treatment for advanced pancreatic cancer, which traditionally has limited effective options.